Overview

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day in patients with severe vernal keratoconjunctivitis after 4 months of treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Santen SAS

Treatments:

Cyclosporine
Cyclosporins